Openbookopenbook
Openbook
CURE
+21.31 · +23.25%
$112.94 · NYSE ARCA

Direxion Daily Healthcare Bull 3X Shares (CURE) ETF Analysis | Trading--Leveraged Equity

Direxion Funds · United States
AUM:$164.3M
#– of – in Trading--Leveraged Equity ETFs

Educational tool only – Figures are based on historical data, holdings and expense metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Market Performance

CURE returned +4.2% over the past year, broadly in line with flat market conditions.

Cost Efficiency

Ongoing charge of 0.96% — above average for this category.

What is CURE?

The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology.

Performance Highlights

Returns (%)
Top Sectors (%)

Investment Breakdown

Modest 1-Year Return
CURE returned 4.2% over the past year.
Higher Cost Profile
Expense ratio of 0.96% is above average. Verify whether the strategy justifies the cost.
Moderate Concentration
Top 10 holdings make up 45.6% of the ETF — a moderate level of name concentration.
ETF Information
AUM$164.3M
Expense Ratio0.96%
Dividend Yield1.14%
Holdings43
Inception DateJun 2011
DomicileUnited States
DistributionNA
Index–
ProviderDirexion Funds
Beta1.75
CategoryTrading--Leveraged Equity
CurrencyUSD
Portfolio Impact

How would CURE affect your portfolio?

Sign in to see exactly what adding this ETF changes — sector exposure, yield, diversification, volatility. Real numbers from your actual holdings.

Sign in
Example preview
6168
+7 points · better diversified

Chart Tools

My Portfolio

Sign in to overlay your portfolio on the chart.

Sign in
Compare Equity
Uses ISF.L (iShares FTSE 100 ETF)
Indicators

Performance Metrics

Historical returns

6M
+13.4%
1Y
+73.8%
3Y
+38.2%
5Y
+13.6%
OpenBook InsightIf you had invested £10,000 in CURE 5 years ago, it would have grown to £11,359 — a gain of £1,359.

Annual Returns

Calendar year performance

CURE delivered positive returns in 2 of the last 5 calendar years.
YearCURE
2026 YTD+20.9%
2025+22.9%
2024-12.9%
2023-8.4%
2022-17.9%
CAGR 4yr-5.3%
2/5 positive yearsAvg return: +0.9%Worst year: -17.9% (2022)

Technical Analysis Summary

Automated insights from historical price action and indicators

Technical Regime: POSITIVE
Trend Strength
100%
Positive
Volatility
53.9%
Very High
Momentum
+21.5%
30-day change
Support Level
117.48
Key floor
Key Insights
  • Price is currently trading above all key moving averages.
  • Momentum is upward with a 21.5% move over 30 days.
  • Elevated volatility indicates higher short-term price variability and risk.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.